menu
    • menu
    [{"orgOrder":0,"company":"Poolbeg Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"POLB 001","moa":"p38","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Poolbeg Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Poolbeg Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Poolbeg Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Poolbeg Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"POLB 001","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Poolbeg Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Poolbeg Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Poolbeg Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Poolbeg Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"POLB 001","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Poolbeg Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Poolbeg Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Poolbeg Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Poolbeg Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Poolbeg Pharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Poolbeg Pharma \/ Undisclosed","highestDevelopmentStatusID":"2","companyTruncated":"Poolbeg Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Poolbeg Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"POLB001","moa":"","graph1":"Immunology","graph2":"Phase I","graph3":"Poolbeg Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Poolbeg Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Poolbeg Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Poolbeg Pharma","sponsor":"Silk Road Therapies","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Pentoxifylline","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Poolbeg Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Poolbeg Pharma \/ Poolbeg Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Poolbeg Pharma \/ Poolbeg Pharma"},{"orgOrder":0,"company":"Poolbeg Pharma","sponsor":"Hookipa Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2025","type":"Merger","leadProduct":"HB-700","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Poolbeg Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Poolbeg Pharma \/ Hookipa Pharma","highestDevelopmentStatusID":"5","companyTruncated":"Poolbeg Pharma \/ Hookipa Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Poolbeg Pharma

    Menu

    Poolbeg Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Poolbeg Pharma

                            United Kingdom arrow
                            OPRD USA
                            Not Confirmed

                            Poolbeg Pharma

                            United Kingdom arrow
                            OPRD USA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HB-700

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Hookipa Pharma

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Poolbeg Pharma Plc Combination of Poolbeg and HOOKIPA Pharma Inc.

                            Details : The combined company will advance the next-generation immunotherapies including, multi-KRAS targeting HB-700, for the treatment of cancer and other serious diseases.

                            Product Name : HB-700

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            January 02, 2025

                            Lead Product(s) : HB-700

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Hookipa Pharma

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Poolbeg Pharma

                            United Kingdom arrow
                            OPRD USA
                            Not Confirmed

                            Poolbeg Pharma

                            United Kingdom arrow
                            OPRD USA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pentoxifylline

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase II

                            Recipient : Silk Road Therapies

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Poolbeg Pharma PLC Announces Option Agreement to Acquire Orphan Drug Candidate

                            Details : Through the agreement with Silk Road Therapeutics to acquire novel topical muco-adherent formulation of Trental (pentoxifylline), for oral ulcers in patients suffering from behcet's disease.

                            Product Name : Trental

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 30, 2024

                            Lead Product(s) : Pentoxifylline

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase II

                            Recipient : Silk Road Therapies

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Poolbeg Pharma

                            United Kingdom arrow
                            OPRD USA
                            Not Confirmed

                            Poolbeg Pharma

                            United Kingdom arrow
                            OPRD USA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : POLB001

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Poolbeg Pharma PLC Announces Further Data Shows POLB001 Potential in Cancer CRS

                            Details : POLB 001 is a novel small molecule, orally administered p38 MAP kinase inhibitor. It is being evaluated under in-vivo studies for the treatment of cytokine release syndrome.

                            Product Name : POLB001

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 17, 2024

                            Lead Product(s) : POLB001

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Poolbeg Pharma

                            United Kingdom arrow
                            OPRD USA
                            Not Confirmed

                            Poolbeg Pharma

                            United Kingdom arrow
                            OPRD USA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Genetic Disease

                            Study Phase : Discovery

                            Sponsor : Undisclosed

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Poolbeg Partners with a Nasdaq-Listed Biopharma

                            Details : Under the collaboration, the Company will produce a prototype drug utilising Poolbeg's licensed oral delivery technology. Poolbeg believes that this technology can help to optimise the delivery of its partner's novel drug to its ideal site of therapeutic...

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            October 17, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Discovery

                            Sponsor : Undisclosed

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Poolbeg Pharma

                            United Kingdom arrow
                            OPRD USA
                            Not Confirmed

                            Poolbeg Pharma

                            United Kingdom arrow
                            OPRD USA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : POLB 001

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Poolbeg Pharma PLC Announces Strategic Expansion of POLB 001 into Oncology

                            Details : POLB 001 reduces hyperinflammation which is associated with CRS, has the potential to significantly reduce the serious adverse effects experienced by many CAR T cell patients.

                            Product Name : POLB 001

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 16, 2023

                            Lead Product(s) : POLB 001

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Poolbeg Pharma

                            United Kingdom arrow
                            OPRD USA
                            Not Confirmed

                            Poolbeg Pharma

                            United Kingdom arrow
                            OPRD USA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : POLB 001

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Poolbeg Pharma PLC - POLB 001 LPS Human Challenge Trial Completed

                            Details : POLB 001 is a unique potential treatment for viruses such as severe influenza as it is strain agnostic, unlike other flu treatments and prophylactics. This means that it can be effective regardless of which strain of influenza is dominant in any particul...

                            Product Name : POLB 001

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 12, 2022

                            Lead Product(s) : POLB 001

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Poolbeg Pharma

                            United Kingdom arrow
                            OPRD USA
                            Not Confirmed

                            Poolbeg Pharma

                            United Kingdom arrow
                            OPRD USA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : POLB 001

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Poolbeg Pharma PLC Announces POLB 001 US Patent Update

                            Details : POLB 001 is a small molecule immunomodulator for the treatment of severe influenza. POLB 001 electively inhibits overwhelming inflammation in viral infections, such as influenza, while leaving the necessary immune functions intact to fight the infection.

                            Product Name : POLB 001

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 04, 2022

                            Lead Product(s) : POLB 001

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth